ArticleAntimicrobial agents and chemotherapy2010
Compensation of fitness costs and reversibility of antibiotic resistance mutations.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Send more data: a systematic review of mathematical models of antimicrobial resistance.Antimicrobial resistance and infection control · 2018Pooled it
- Trial
- BamA as a next-generation antibacterial target: mechanistic insights, inhibitor landscape, and rational drug design strategies.RSC advances · 2026Review
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- Modelling the role of the microbiome in antimicrobial resistance across scales.Nature microbiology · 2026Review
- Lifestyle-dependent evolution and CtrA-mediated lifestyle transitions shape phage resistance in marine Roseobacter.Nature communications · 2026Article
- Epidemiology and antimicrobial resistance ofInfectious diseases (London, England) · 2026Article
- Molecular insights into antimicrobial resistance in human bacterial pathogens: mechanisms, resistance genes, and translational diagnostic applications.Frontiers in microbiology · 2026Review
- Complex genotype-phenotype relationships shape the response to treatment of down syndrome childhood acute lymphoblastic leukaemia.Scientific reports · 2025Article
- The diverse phenotypic and mutational landscape induced by fluoroquinolone treatment.mSystems · 2025Article
- Core Perturbomes ofPathogens (Basel, Switzerland) · 2025Article
- Epistasis-mediated compensatory evolution in a fitness landscape with adaptational tradeoffs.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Fluoroquinolone-specific resistance trajectories in E. coli and their dependence on the SOS-response.BMC microbiology · 2025Article
- An eco-evolutionary perspective on antimicrobial resistance in the context of One Health.iScience · 2025Review
- Patterns ofFrontiers in tuberculosis · 2025Article
- The emergence of nonlinear evolutionary trade-offs and the maintenance of genetic polymorphisms.Biology letters · 2024Article
- Context-dependent fitness benefits of antibiotic resistance mutations.Proceedings. Biological sciences · 2024Article
- Article
- The Emergence of Non-Linear Evolutionary Trade-offs and the Maintenance of Genetic Polymorphisms.bioRxiv : the preprint server for biology · 2024Article
- Upregulated Palmitoleate and Oleate Production inMolecules (Basel, Switzerland) · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Strains of bacterial pathogens that have acquired mutations conferring antibiotic resistance often have a lower growth rate and are less invasive or transmissible initially than their susceptible counterparts. However, fitness costs of resistance mutations can be ameliorated by secondary site mutations. These so-called compensatory mutations may restore fitness in the absence and/or presence of antimicrobials. We review literature data and show that the fitness gains in the absence and presence of antibiotic treatment need not be correlated. The aim of this study is to gain a better conceptual grasp of how compensatory mutations with different fitness gains affect evolutionary trajectories, in particular reversibility. To this end, we developed a theoretical model with which we consider both a resistance and a compensation locus. We propose an intuitively understandable parameterization for the fitness values of the four resulting genotypes (wild type, resistance mutation only, compensatory mutation only, and both mutations) in the absence and presence of treatment. The differential fitness gains, together with the turnover rate and the mutation rate, strongly affected the success of antibacterial treatment, reversibility, and long-term abundance of resistant strains. We therefore propose that experimental studies of compensatory mutations should include fitness measurements of all possible genotypes in both the absence and presence of an antibiotic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.